Merck Hits Brakes On Anti-PD-1/TIGIT Study In Adjuvant Melanoma
Industry-wide, the combination of PD-1/PD-L1 inhibitors with TIGIT inhibitors has produced a mixed bag in terms of results.
Industry-wide, the combination of PD-1/PD-L1 inhibitors with TIGIT inhibitors has produced a mixed bag in terms of results.